Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Mimedx Group Inc. is managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners and 3 distinct art units, indicating a diversified prosecution front. FOX, ALLISON M is the busiest examiner, currently overseeing 1 busiest examiner pending action.
The distribution across 3 distinct art units shows that the portfolio covers a range of biotechnology subjects. With 3 distinct examiners involved, the company must manage three different prosecution styles simultaneously. However, because the busiest examiner pending count is only 1, the workload is perfectly spread, and no single examiner currently dominates the company's immediate legal hurdles.
Practitioners should note that having 3 distinct examiners for 3 pending office actions provides the maximum possible examiner diversity for this workload. This allows the company to see how different individuals respond to their technical claims across various art units. Success in this portfolio requires maintaining consistent arguments across the 3 distinct art units while addressing the specific requirements of FOX, ALLISON M and the other two examiners.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEONARD, ARTHUR S | 1 | 50.5% | +50.4% |
| FOX, ALLISON M | 1 | 71.0% | +35.7% |
| PRONE, CHRISTOPHER D | 1 | 65.0% | +18.9% |
| DAVIS, RUTH A | 1 | 60.9% | +31.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18296207 | LYOPHILIZED PERFORATED PLACENTAL MEMBRANE TISSUE GRAFTS | LEONARD, ARTHUR S | 70d |
| 17518685 | MESHED PLACENTAL MEMBRANE TISSUE GRAFTS | PRONE, CHRISTOPHER D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17980910 | PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME | FOX, ALLISON M | 42d overdue |
| 18296207 | LYOPHILIZED PERFORATED PLACENTAL MEMBRANE TISSUE GRAFTS | LEONARD, ARTHUR S | 70d |
| 17518685 | MESHED PLACENTAL MEMBRANE TISSUE GRAFTS | PRONE, CHRISTOPHER D | — |
| 17069726 | METHOD FOR INDUCING ANGIOGENESIS | DAVIS, RUTH A | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1633 | 1 |
| 3774 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18296207 | LYOPHILIZED PERFORATED PLACENTAL MEMBRANE TISSUE GRAFTS | LEONARD, ARTHUR S | 1631 | §102§103§112 | Final Rejection | 70d | Pending | Apr 05, 2023 |
| 17980910 | PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME | FOX, ALLISON M | 1633 | §103 | Final Rejection | 42d overdue | Pending | Nov 04, 2022 |
| 17518685 | MESHED PLACENTAL MEMBRANE TISSUE GRAFTS | PRONE, CHRISTOPHER D | 3774 | §103§112 | Non-Final OA | — | Pending | Nov 04, 2021 |
| 17069726 | METHOD FOR INDUCING ANGIOGENESIS | DAVIS, RUTH A | 1699 | §112 | Final Rejection | — | Pending | Oct 13, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMimedx Group Inc. has 4 pending office actions as of November 2026, spread across 4 art units and 4 examiners.
Arthur S Leonard has the most, with 1 of Mimedx Group Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.